Teleflex (TFX) AI Stock Analysis

• Market Cap: $4.80B
• Dividend Yield: 1.09%
• Average Volume (3M): 565.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: 5.43%
• EPS Growth: -245.18%
• Country: US
• Employees: 14,100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 3.67
• Shares Outstanding: 44,192,818
• 10 Day Avg. Volume: 713,597
• 30 Day Avg. Volume: 565,219
• PEG Ratio: -1.49
• Price to Book (P/B): 1.95
• Price to Sales (P/S): 2.74
• P/FCF Ratio: 16.37
• Enterprise Value/Market Cap: 1.61
• Enterprise Value/Revenue: 2.42
• Enterprise Value/Gross Profit: 4.51
• Enterprise Value/Ebitda: 21.97
• 1Y Price Target: $137.50
• Price Target Upside: 10.22% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 14.09
• Revenue Forecast (FY): $3.32B

• Rating: 60 Neutral
• Price Target: $114.00 ▼(-8.62% Downside)

Teleflex's overall stock score reflects a mixed outlook. The most significant factor is the company's financial performance, which shows positive revenue growth but weak profitability. Technical analysis indicates bearish momentum, adding downside risk. Valuation is high, limiting upside potential. The earnings call provides some optimism with strong revenue growth guidance, but margin pressures remain a concern.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Teleflex's products and successful market penetration, supporting long-term business expansion.

Successful Integration

Effective integration of acquisitions can enhance operational efficiency and expand product offerings, strengthening competitive positioning.

Global Expansion

Expanding into new markets like Japan can diversify revenue streams and reduce dependency on existing markets, fostering long-term growth.

Negative Factors

Profitability Challenges

Negative profitability indicates operational challenges and could hinder reinvestment in growth initiatives, affecting long-term sustainability.

Margin Pressure

Decreasing margins can limit profitability and reduce the ability to invest in new opportunities, impacting future growth potential.

Free Cash Flow Decline

Reduced free cash flow growth may limit the company's ability to fund new projects or acquisitions, constraining long-term expansion.

Teleflex Business Overview & Revenue Model

Company Description

Teleflex Incorporated (TFX) is a global provider of medical technologies designed to improve the health and quality of people's lives. The company operates in various sectors, including vascular access, anesthesia, respiratory care, and surgical devices. Teleflex offers a wide range of products, including catheters, surgical instruments, and devices for managing airway and vascular access, focusing on innovation and high-quality outcomes for healthcare professionals and patients.

How the Company Makes Money

Teleflex generates revenue primarily through the sale of its medical devices and products across different healthcare sectors. The company has a diversified revenue model that includes direct sales to healthcare providers, hospitals, and other medical institutions. Key revenue streams include vascular access products, anesthesia products, and surgical instruments. Additionally, Teleflex benefits from strategic partnerships and collaborations with healthcare organizations and distributors, which enhance its market reach and product availability. The company's focus on innovation and development of new products also contributes significantly to its earnings, as it meets the evolving needs of the healthcare market.

Teleflex Financial Statement Overview

Summary

Teleflex shows mixed financial performance. Revenue growth is positive at 4.89%, but profitability metrics are weak with a negative net profit margin of -10.28%. The balance sheet is strong with low leverage, but the negative ROE is concerning. Cash flow generation is adequate, but declining free cash flow growth poses a risk.

Income Statement

Teleflex's income statement shows a mixed performance. The company has experienced a positive revenue growth rate of 4.89% in the TTM, indicating a healthy top-line expansion. However, the net profit margin has turned negative at -10.28% in the TTM, primarily due to a significant net loss. The gross profit margin remains stable at around 53.67%, but the decline in EBIT and EBITDA margins suggests challenges in operational efficiency.

Balance Sheet

Teleflex's balance sheet reflects a solid equity position with a low debt-to-equity ratio of 0.052 in the TTM, indicating low financial leverage. However, the return on equity has turned negative at -7.98%, highlighting profitability challenges. The equity ratio remains strong, suggesting a stable capital structure.

Cash Flow

The cash flow statement shows a decline in free cash flow growth by -16.69% in the TTM, which could impact future investments. The operating cash flow to net income ratio is 0.51, indicating moderate cash generation relative to net income. The free cash flow to net income ratio is high at 0.92, suggesting efficient cash conversion despite the net loss.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.19B	3.05B	2.97B	2.79B	2.81B	2.54B
Gross Profit	1.71B	1.70B	1.65B	1.53B	1.55B	1.32B
EBITDA	351.45M	433.62M	761.21M	730.77M	853.80M	651.48M
Net Income	-327.97M	69.67M	356.33M	363.14M	485.37M	335.32M
Balance Sheet
Total Assets	7.87B	7.10B	7.53B	6.93B	6.87B	7.15B
Cash, Cash Equivalents and Short-Term Investments	354.00M	306.16M	222.85M	292.03M	445.08M	375.88M
Total Debt	197.65M	1.76B	1.93B	1.83B	1.97B	2.56B
Total Liabilities	4.05B	2.82B	3.09B	2.91B	3.12B	3.82B
Stockholders Equity	3.82B	4.28B	4.44B	4.02B	3.75B	3.34B
Cash Flow
Free Cash Flow	359.42M	509.31M	419.20M	262.95M	579.80M	345.71M
Operating Cash Flow	391.44M	635.74M	510.64M	342.14M	651.42M	436.41M
Investing Cash Flow	-908.84M	-99.36M	-621.23M	-257.94M	156.74M	-837.78M
Financing Cash Flow	-142.78M	-421.93M	38.54M	-217.51M	-715.82M	455.16M

Teleflex Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 124.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TFX, the sentiment is Negative. The current price of 124.75 is below the 20-day moving average (MA) of 125.35, below the 50-day MA of 125.62, and below the 200-day MA of 131.02, indicating a bearish trend. The MACD of -2.49 indicates Positive momentum. The RSI at 28.58 is Positive, neither overbought nor oversold. The STOCH value of 25.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TFX.

Teleflex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	78 Outperform	$5.19B	44.81	8.30%	―	11.49%	-2.89%
LMAT	75 Outperform	$1.95B	41.90	15.02%	0.88%	13.07%	27.98%
HAE	70 Outperform	$3.20B	19.94	19.47%	―	-2.45%	41.50%
TFX	60 Neutral	$4.80B	―	-7.90%	1.09%	5.43%	-245.18%
ICUI	57 Neutral	$3.10B	-82.51	-1.78%	―	-0.81%	93.27%
BLCO	56 Neutral	$5.50B	―	-4.69%	―	6.23%	17.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Teleflex Corporate Events

Teleflex Reports Strong Revenue Growth Amid Challenges

Teleflex Incorporated is a global provider of medical technologies, specializing in areas such as anesthesia, emergency medicine, interventional cardiology, and surgical and urology products. The company is known for its diverse portfolio of trusted brands and its commitment to improving healthcare outcomes.

Teleflex’s Earnings Call: Growth Amid Challenges

Teleflex’s recent earnings call revealed a balanced sentiment, highlighting both strengths and challenges faced by the company. The call showcased impressive revenue growth and successful integration of recent acquisitions, yet acknowledged difficulties in certain product lines and regions that have impacted margins, leading to a revision in revenue guidance.

Teleflex Reports Strong Q3 2025 Financial Results

Teleflex announced its financial results for the third quarter ending September 28, 2025, reporting a 19.4% increase in GAAP revenue compared to the previous year. Despite a decrease in order rates for its intra-aortic balloon pump portfolio, the company exceeded expectations in adjusted operating margin and earnings per share. Teleflex is also narrowing its revenue growth guidance for 2025 and continues to focus on its strategy to drive shareholder value, including the potential sale of its NewCo division.

The most recent analyst rating on (TFX) stock is a Buy with a $132.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.

Teleflex’s AE05ML Device Study: A Potential Game-Changer in Laparoscopic Surgery

Teleflex is conducting a clinical registry study titled ‘A Prospective, Observational Clinical Registry Study to Assess Safety and Performance of AE05ML Device for ML Hem-o-lok Polymer Clip Delivery in Laparoscopic Surgical Procedures.’ The study’s primary goal is to evaluate the safety and effectiveness of the AE05ML device in delivering Hem-o-lok Medium Large polymer clips during laparoscopic surgeries. This research is significant as it aims to enhance surgical outcomes by ensuring the device’s reliability and safety.